Clinical Ink’s Jonathan Andrus Invited to Speak at the Duke-Margolis Center for Health Policy Public Meeting
June 13, 2019
Horsham, PA.; June 13, 2019 – Clinical Ink, a global clinical trial technology company that is transforming the clinical trial experience, is pleased to announce that Jonathan Andrus, chief business officer at Clinical Ink, has been invited to be a panelist in a public meeting hosted by the Duke-Margolis Center for Health Policy on July 17, 2019, in Washington, D.C. The workshop, convened under a cooperative agreement with the FDA, will discuss opportunities to improve the implementation of risk-based monitoring (RBM) in clinical investigations.
Andrus will participate as a key expert alongside Ann Meeker-O’Connell of IQVIA and Mike Henderson of SAS for the session, “Analytical Tools and Methods to Support Risk-Based Monitoring.” The panelists will explore available analytic approaches, technology, and tools that could support the implementation of RBM.
“Understanding why RBM approaches have not been widely adopted and what can be done to encourage their use will benefit the entire global pharma and biotech industry,” said Andrus. “I’m honored to have been selected to participate in this discussion.”
RBM allows sponsors to concentrate their oversight on the most critical, highest risk data elements, procedures, and processes necessary to achieve the objectives of their clinical investigations. This workshop brings together thought leaders from the FDA, EMA, ACRO, BIO, TransCelerate, and more to discuss the challenges, barriers, and enablers that influence the adoption of RBM and opportunities to improve its implementation.
About Clinical Ink
Clinical Ink is a global clinical trial technology company that is transforming the clinical trial experience. Founded in 2007, the company’s proven and future-built eSource platform, which includes solutions for EDC replacement, eCOA, ePRO, and more, accelerates time to value while delivering scientific results that matter. With offices in Winston-Salem, NC, and Philadelphia, PA, Clinical Ink is advancing the business model responsible for bringing new treatments to market.